Try our Advanced Search for more refined results
Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.
Case Number:
16-1284
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
January 26, 2018
High Court Denies Helsinn's Bid To Stay On-Sale Bar Ruling
The U.S. Supreme Court on Thursday shot down Helsinn Healthcare's bid to hit pause on a Federal Circuit decision invalidating four Helsinn patents related to an anti-nausea drug under the America Invents Act's on-sale bar, refusing to hold up the ruling while the pharmaceutical company pursues a high court review of the case.
-
January 19, 2018
Helsinn Wants On-Sale Bar Ruling Held For High Court Appeal
The Federal Circuit has given Teva Pharmaceuticals until Monday to reply to Helsinn Healthcare's last-ditch bid to keep Teva from launching a generic version of Helsinn's Aloxi anti-nausea drug while it seeks to take its patent case to the U.S. Supreme Court.
-
January 16, 2018
Fed. Circ. Clarifies But Won't Redo AIA On-Sale Bar Ruling
The Federal Circuit on Tuesday said it won't reconsider invalidating four Helsinn Healthcare SA nausea drug patents in a ruling over the scope of the America Invents Act's on-sale bar, but clarified that its decision isn't as extreme as the intellectual property world feared.
-
July 19, 2017
Major IP Groups Urge Full Fed. Circ. To Eye AIA On-Sale Bar
Many major intellectual property groups urged the full Federal Circuit on Wednesday to review a decision that sales in which an invention isn't publicly disclosed invalidate patents under the America Invents Act's on-sale bar rule, with one saying the ruling threatens to "destabilize the entire U.S. patent system."
-
July 11, 2017
AIA Sponsor Wants Full Fed. Circ. To Weigh On-Sale Bar Rule
U.S. Rep. Lamar Smith, R-Texas, urged the full Federal Circuit on Tuesday to review a panel decision that the America Invents Act's on-sale bar rule renders patents invalid if the invention was sold prior to patenting even if the sale did not publicly disclose the invention, saying it's not what Congress intended.
-
July 05, 2017
Fed. Circ. Asked To Rehear Patent On-Sale Bar Case En Banc
Helsinn Healthcare SA has requested that the Federal Circuit rehear en banc a case over the scope of the America Invents Act's on-sale bar, arguing that an earlier ruling "subverts" the AIA's "carefully constructed statutory scheme."
-
May 03, 2017
Fed. Circ. Suggests AIA May Not Have Weakened On-Sale Bar
The Federal Circuit has declined to issue a broad ruling on whether the America Invents Act altered the on-sale bar rule, which specifies that sales made before a patent application is filed can render the patent invalid, yet its holding that sales that don't publicly disclose an invention can invalidate a patent suggests the rule may not have lost its teeth, attorneys say.
-
May 01, 2017
Fed. Circ. Defines Scope Of AIA On-Sale Bar Rule
The Federal Circuit ruled Monday that the America Invents Act's on-sale bar provision renders patents invalid if the invention was sold prior to patenting even if the sale did not publicly disclose the invention, reversing a lower court and invalidating four Helsinn Healthcare SA nausea drug patents.
-
October 04, 2016
Congress Clear About AIA's On-Sale Bar, Patent Office Says
In passing the America Invents Act, Congress clearly intended that only public sales trigger the on-sale bar that invalidates patents, the U.S. Patent and Trademark Office told a Federal Circuit panel Tuesday, backing patent holder Helsinn Healthcare SA in a dispute that pits the 2011 measure against decades of patent law precedent.
-
September 30, 2016
Fed. Circ. On-Sale Bar Case Could Make Axing Patents Harder
The Federal Circuit could decide in a case set for arguments Tuesday that the America Invents Act's on-sale bar provision covers only sales to the public, a holding that would protect many patents from being invalidated and mark a shift from decades of precedent, attorneys say.